Unknown

Dataset Information

0

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.


ABSTRACT: BACKGROUND:ER-positive (ER+) breast cancer includes all of the intrinsic molecular subtypes, although the luminal A and B subtypes predominate. In this study, we evaluated the ability of six clinically relevant genomic signatures to predict relapse in patients with ER+ tumors treated with adjuvant tamoxifen only. METHODS:Four microarray datasets were combined and research-based versions of PAM50 intrinsic subtyping and risk of relapse (PAM50-ROR) score, 21-gene recurrence score (OncotypeDX), Mammaprint, Rotterdam 76 gene, index of sensitivity to endocrine therapy (SET) and an estrogen-induced gene set were evaluated. Distant relapse-free survival (DRFS) was estimated by Kaplan-Meier and log-rank tests, and multivariable analyses were done using Cox regression analysis. Harrell's C-index was also used to estimate performance. RESULTS:All signatures were prognostic in patients with ER+ node-negative tumors, whereas most were prognostic in ER+ node-positive disease. Among the signatures evaluated, PAM50-ROR, OncotypeDX, Mammaprint and SET were consistently found to be independent predictors of relapse. A combination of all signatures significantly increased the performance prediction. Importantly, low-risk tumors (>90% DRFS at 8.5 years) were identified by the majority of signatures only within node-negative disease, and these tumors were mostly luminal A (78%-100%). CONCLUSIONS:Most established genomic signatures were successful in outcome predictions in ER+ breast cancer and provided statistically independent information. From a clinical perspective, multiple signatures combined together most accurately predicted outcome, but a common finding was that each signature identified a subset of luminal A patients with node-negative disease who might be considered suitable candidates for adjuvant endocrine therapy alone.

SUBMITTER: Prat A 

PROVIDER: S-EPMC3477878 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.

Prat A A   Parker J S JS   Fan C C   Cheang M C U MCU   Miller L D LD   Bergh J J   Chia S K L SKL   Bernard P S PS   Nielsen T O TO   Ellis M J MJ   Carey L A LA   Perou C M CM  

Annals of oncology : official journal of the European Society for Medical Oncology 20120424 11


<h4>Background</h4>ER-positive (ER+) breast cancer includes all of the intrinsic molecular subtypes, although the luminal A and B subtypes predominate. In this study, we evaluated the ability of six clinically relevant genomic signatures to predict relapse in patients with ER+ tumors treated with adjuvant tamoxifen only.<h4>Methods</h4>Four microarray datasets were combined and research-based versions of PAM50 intrinsic subtyping and risk of relapse (PAM50-ROR) score, 21-gene recurrence score (O  ...[more]

Similar Datasets

| S-ECPF-GEOD-46823 | biostudies-other
2015-08-21 | PXD000484 | Pride
2015-08-21 | PXD000485 | Pride
| S-EPMC4713329 | biostudies-literature
| S-EPMC5055383 | biostudies-literature
| S-EPMC8307977 | biostudies-literature